Note: F3 Platform Biologics Inc. withdrew its IPO plans in a letter to the SEC on June 20, 2024. The company had filed to go public in 2023.(Incorporated in Delaware)

We are a late-stage biopharmaceutical company focused on the research, clinical development and ultimate commercialization of new indications surrounding amifostine, a compound previously approved by the FDA to prevent and treat side effects related to cancer treatment and radiation therapy. (Incorporated in Delaware)

F3 Platform Biologics, Inc. (the “Company”) was incorporated in the State of Delaware on June 5, 2018. The Company is a late-stage biopharmaceutical company committed to the development and commercialization of novel, practical biotechnology for human use. The Company is concentrating its present efforts on the clinical development for new indications of the drug amifostine, the only FDA-approved radiation protection drug. The Company believes that its scientific and preclinical data has demonstrated that at doses less than 80 to 90% of the current FDA-approved amount, amifostine can protect and repair the genomic damage and instability that occurs when human cells are exposed to low dose amounts of ionizing radiation such as those present in a CT scan. Additionally, the Company has a pipeline of other indications for the cytoprotectant compound amifostine. Currently, the Company is completely focused on its lead drug product, AmiGuard CT, which provides cytoprotection against radiation-induced genomic damage and instability caused by CT scans.

SIC 2834